Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RADOO1 (Everolimus)

Next Previous
Search
Trial Profile

Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RADOO1 (Everolimus)

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 13 Apr 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Everolimus (Primary)
  • Indications Renal cancer
  • Focus Biomarker; Therapeutic Use

    • Most Recent Events

    • 08 Jun 2010 Study details were reported at ASCO 2010.
    • 02 Sep 2009 Planned end date (Dec 2011) added as reported by ClinicalTrials.gov.
    • 02 Sep 2009 Actual initiation date (Aug 2008) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top